Navigation Links
HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments
Date:10/6/2011

BRANFORD, Conn., Oct. 6, 2011 /PRNewswire/ -- HistoRx, the leader in quantitative immunohistochemistry, advances its proprietary position in digital pathology through the recent issuance of US patents covering key features necessary for achievement of reproducible, standardized image analysis results.  The U.S. Patent and Trademark Office has granted two new patents protecting the company's methods for standardization of digital microscopy instruments, methods required to generate high-quality reproducible clinical diagnostic data that precisely relates to biomarker concentrations in tissue sections.

For patient tissue specimens stained for a biomarker such as HER2, HistoRx believes that physicians and patients expect the same quantitative result regardless of the digital microscopy instrument used.  To achieve this, HistoRx evaluated sources of variability in digital scanning microscopy instrumentation that affect results.  One source of variability is the light source; a second is the path traveled by the light through each instrument.  By correcting for each of these, HistoRx achieved exceptionally high levels of reproducibility for an assay previously thought to be incapable of true standardization: with AQUA® technology, the same slide of breast cancer specimens stained for HER2 analyzed across five instruments standardized by this method attained a coefficient of variance of less than 5% (where typical variances are ~20%).

"These patents reinforce the value of HistoRx's unique approach to achieving objectivity and reproducibility in anatomic pathology," said Mark Gustavson, Ph.D., Director of Operations at HistoRx and one of the inventors.  "You cannot have clinical accuracy without analytical precision."

US Patent 7,978,258, issued to HistoRx on July 12, 2011, is entitled "Automatic Exposure Time Selection for Imaging Tissue" and pertains to methods for determining appropriate exposure time for acquiring digital images intended for image analysis to generate quantitative results.  Exposure times are most commonly determined to optimize contrast and visual appeal of the image, and may be determined 'by eye.'  The human eye is a poor judge of intensity, and images generated by conventionally determined exposure times are commonly too overexposed for generating quantitative results.  The patented methods automatically determine the appropriate exposure time to maximize for a broad range of pixel intensities in the image, thereby maximizing the dynamic range of quantitative measurements achievable from subsequent image analysis.

US Patent 8,027,030, issued to HistoRx on September 26, 2011, is entitled "Methods and System for Standardizing Microscope Systems," and pertains to hardware that can be inserted into the digital imaging fluorescent microscopy system, similar to filter cubes used in fluorescence microscopy, and provides for the monitoring of the light source and its fluctuation.  

AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with conventional testing methods, such as standard immunohistochemistry (IHC).  AQUA analysis is used in cancer research by twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  The first use of AQUA technology in the clinical diagnostic setting occurred in 2010 with the launch by Genoptix Inc. of diagnostic tests based on AQUA technology licensed from HistoRx.  AQUA technology is currently available on the ScanScope FL™ from Aperio and will be available later this year on the Vectra™ system from Caliper Life Sciences.

About HistoRx, Inc.

HistoRx, Inc. is the leader in quantitative immunohistochemistry and a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology.  AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
2. HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology
3. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
4. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
5. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
6. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
7. Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America
8. VIDA Diagnostics Earns ISO 13485 and CE Certifications
9. Aprima Earns High Marks at Holy Name Medical Center
10. Sevocity Division of Conceptual MindWorks Inc.s Sevocity EHR Earns CCHIT 2011 Certification
11. Isis Earns $3 Million Payment as Collaboration With GSK Expands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... Grocery Company to the list of fine retailers selling biodegradable, hanging flushable wipes ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more than ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... MA (PRWEB) , ... April 28, 2017 , ... People ... for older people. “Wearing a hearing aid doesn’t have the stigma it had when ... & Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
Breaking Medicine News(10 mins):